NCT06028932 2026-03-05A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsYale UniversityPhase 2 Active not recruiting20 enrolled
NCT06040970 2025-12-02Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerIcahn School of Medicine at Mount SinaiPhase 1/2 Recruiting54 enrolled